Homeobox A9-recognition DNA sequence (HOXA9-DNA)

The Homeobox A9 (HOXA9)-recognition DNA sequence is the specific genomic site, often characterized by a 5'-TTTAT-3' or 5'-TAAT-3' core motif, where the HOXA9 transcription factor binds to regulate gene expression (UniProt P31269). HOXA9 is a critical regulator of hematopoietic stem cell expansion and differentiation, but its constitutive overexpression is a primary driver in aggressive leukemias, including those with MLL rearrangements or NPM1 mutations (PMID: 27516441). By binding to these DNA sequences, HOXA9 forms complexes with co-factors like PBX1 and MEIS1 to activate oncogenic pathways that block myeloid differentiation and promote leukemogenesis (PMID: 30333116). Therapeutic strategies targeting this interaction include the development of DNA decoys—short, synthetic DNA fragments that mimic the recognition sequence—to sequester HOXA9 away from its genomic targets (PMID: 24970811). Additionally, small molecules and peptides like HXR9 have been developed to disrupt the interaction between HOXA9 and its DNA-binding partners, effectively preventing the protein from occupying its recognition sequences (PMID: 17460774). These approaches aim to silence the HOXA9-driven transcriptional program, offering a potential treatment for refractory myeloid malignancies.

Other names

HOXA9 binding siteHOXA9 response elementHOXA9 consensus sequenceHOXA9-DNA binding motif

Competitive inhibition of transcription factor binding via decoy oligonucleotides or disruption of the HOXA9-DNA interface.